You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 中生製藥(1177.HK)高開4.86% 首季純利同比大增118.5%
格隆匯 05-25 09:28
格隆匯5月25日丨中國生物製藥(1177.HK)跳空高開4.86%,報9.49港元,股價創去年8月20日以來逾9個月新高,暫成交1億港元,最新市值1789億港元。中生製藥昨日晚間公佈截至3月31日止三個月業績稱,集團收入約為72.43億元(人民幣,下同),同比增長約16.4%;毛利約為58.27億元,同比增長約17.6%;歸屬於母公司持有者應占盈利約19.14億元,同比增長約118.5%。派發股息每股2港仙。集團繼續專注肝病、抗腫瘤、呼吸系統和心腦血管等治療領域的新產品研發。於第一季度內,集團獲得臨牀批件7件、生產批件7件及一致性評價獲批12個、申報臨牀8件、一致性評價申報4個及申報生產2個。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account